Senseonics: Eversense 365 Receives FDA Clearance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Eversense 365 Receives FDA Clearance: The World’s First One Year CGM
September 17, 2024 7:00 AM EDTEversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes
With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGMs for minimal life disruption
Launch expected early in the fourth quarter of 2024
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose... More
